Status:
COMPLETED
Angelman Syndrome (AS) Biomarker Study
Lead Sponsor:
Biogen
Conditions:
Angelman Syndrome
Chromosome 15q Duplication (dup15q) Syndrome
Eligibility:
All Genders
Up to 50 years
Phase:
EARLY_PHASE1
Brief Summary
The primary objective of this study is to measure ubiquitin-protein ligase E3A (UBE3A) protein levels in cerebrospinal fluid (CSF) and to evaluate its utility as a biomarker in support of the developm...
Eligibility Criteria
Inclusion
- Key
- Ability of the participant's legally authorized representative (LAR) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local privacy regulations
- Must have genetically confirmed diagnosis of AS (UBE3A deletion, UBE3A mutation, paternal uniparental disomy, or imprinting center defect) or dup15q syndrome (with number and size of duplications of 15q specified) provided by the Investigator
- Must be scheduled for a procedure unrelated to the study that will involve administration of general anesthesia or conscious sedation.
- Key
Exclusion
- Lumbar Puncture (LP) procedure less than 30 days before the Sampling Visit
- Any contraindications to having an LP
- The blood and CSF collection will, in the opinion of the Investigator, inhibit, in some way, the prescheduled procedure that requires anesthesia or sedation
- Current enrollment or past enrollment in an interventional clinical study in which an investigational gene therapy or antisense oligonucleotide (ASO) is/was administered
- Enrollment in an interventional clinical study in which an investigational small molecule/antibody treatment or approved small molecule/antibody therapy is administered within 1 month (or 5 half-lives of study agent, whichever is longer) prior to the Sampling Visit which, under the judgement of the Investigator and/or Sponsor would affect UBE3A and other CSF biomarker levels. Use of approved or investigational small molecule therapies which would not impact the biomarkers above will be eligible with Sponsor approval prior to enrollment (e.g., anti-epileptic drugs being studied in alternative formulation, other derivatives of benzodiazepines, or other same class drugs as those already permitted as part of the study).
- Note: Other protocol defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
December 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 2 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04103333
Start Date
December 18 2019
End Date
January 2 2022
Last Update
January 28 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Rady Childrens Hospital
San Diego, California, United States, 92123
2
Rush Medical College
Chicago, Illinois, United States, 60612
3
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
4
University of North Carolina Hospital
Carolina, North Carolina, United States, 27514